BIOGEN INC. (BIIB)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,382.7M
Cash & Equivalents
$645.5M
Quarterly Burn Rate
$29,402M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (6 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
DACLIZUMAB
ZINBRYTA |
APPROVED | 4H Syndrome, Active Cutaneous Lupus Erythematosus, Active Ulcerative Colitis, Acute Brainstem/Cerebellar Syndrome, Acute Disseminated Encephalomyelitis, Acute Interstitial Pneumonitis, Acute Ischemic Stroke, Acute Optic Neuritis, Acute-graft-versus-host Disease, ADLD, ADPKD, Adrenoleukodystrophy, Adrenomyeloneuropathy, Advanced Solid Tumors, AGS, Aicardi Goutieres Syndrome, ALD, ALD (Adrenoleukodystrophy), ALD Gene Mutation, Alexander Disease, Alexanders Leukodystrophy, Allan-Herndon-Dudley Syndrome, Alport Syndrome, ALS, ALS (Amyotrophic Lateral Sclerosis), ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation, ALSP, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease Dementia, Ambulatory Spinal Muscular Atrophy, AMN, Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, Anaplastic Astrocytoma, Angelman Syndrome, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephali |
|
INTERFERON BETA-1A
AVONEX |
APPROVED | — |
|
DIMETHYL FUMARATE
TECFIDERA |
APPROVED | — |
|
DIROXIMEL FUMARATE
VUMERITY |
APPROVED | — |
|
ZURANOLONE
ZURZUVAE |
APPROVED | — |
|
NUSINERSEN SODIUM
SPINRAZA |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-25 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT01848028 | PsoBest - The German Psoriasis Registry | OTHER | Recruiting | 3,500 |
| NCT05866419 | Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy | OTHER | Recruiting | 90 |
| NCT04468659 | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical A... | PHASE3 | Active Not Recruiting | 1,400 |
| NCT06555419 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and ... | PHASE1 | Recruiting | 58 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.